生物制剂治疗克罗恩病:来自前瞻性澳大利亚国家IBD队列(PANIC3)研究的倾向评分匹配分析
基于澳大利亚国家药品补贴计划2005至2019年前瞻性配药数据,分析1446例克罗恩病患者共2029个治疗线次的生物制剂持续使用情况。倾向评分匹配后,生物制剂初治患者中各药物持续率无差异,而经治患者中乌司奴单抗持续率优于抗TNF制剂和维得利珠单抗。
要点
- 生物制剂初治克罗恩病患者中,阿达木单抗、英夫利西单抗、维得利珠单抗和乌司奴单抗的持续率无显著差异(P>0.05)。
- 生物制剂经治患者中,乌司奴单抗持续率显著优于非乌司奴单抗生物制剂(P=0.0018)、抗TNFα治疗(P=0.006)和维得利珠单抗(P<0.001)。
- 使用非乌司奴单抗生物制剂(校正风险比2.10,P<0.001)和生物制剂经治状态(校正风险比1.23,P<0.001)是多变量预测持续率更差的独立因素。
核心结论
- 在生物制剂初治的克罗恩病患者中,未发现任何一种生物制剂持续率更优;在生物制剂经治患者中,乌司奴单抗的持续率更高。
研究设计与样本
- 前瞻性收集的澳大利亚国家药品补贴计划配药数据登记库(2005-2019年)分析,覆盖克罗恩病,采用倾向评分匹配以减少选择偏倚,共纳入1446例患者、2029个治疗线次,中位年龄43岁(四分位距34-58),44%为男性,随访5618患者年。
主要发现
- 每个治疗线次中,915/2029(45.1%)使用阿达木单抗,722/2029(35.6%)使用英夫利西单抗,155/2029(7.6%)使用维得利珠单抗,237/2029(11.7%)使用乌司奴单抗。
- 生物制剂初治患者中,各药物持续率无差异(P>0.05)。
- 生物制剂经治患者中,乌司奴单抗持续率显著优于非乌司奴单抗生物制剂(P=0.0018)、抗TNFα治疗(P=0.006)和维得利珠单抗(P<0.001);乌司奴单抗的持续率不受既往生物制剂暴露影响(P=0.51)。
- 抗TNF使用后,乌司奴单抗持续率优于换用另一种抗TNF制剂(P=0.033)和维得利珠单抗(P=0.026)。
- 倾向评分匹配分析校正年龄、免疫调节剂使用和生物制剂暴露状态后,乌司奴单抗持续率优于抗TNF(P=0.01);多变量预测持续率更差的因素包括使用非乌司奴单抗生物制剂(校正风险比2.10,P<0.001)和生物制剂经治状态(校正风险比1.23,P<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Comparative effectiveness research provides data on the relative benefits and risks between treatments. In Crohn's disease (CD), however, there are few head-to-head studies comparing advanced therapies and none with long-term follow-up. Real-world effectiveness, defined by treatment persistence, obtained from prospective population-based patient cohorts, may help determine the best sequencing and positioning of biological agents. METHODS: We analyzed the prospectively collected population-based Australian national Pharmaceutical Benefits Scheme dispensing data registry (2005-2019) for CD. There is no mandated biological agent prescribing order, and all citizens and permanent residents are eligible for treatment irrespective of insurance status. Propensity score matching was performed to reduce selection bias. RESULTS: There were 2,029 lines of therapy in 1,446 patients (median age 43 years, interquartile range 34-58, 44% male patients) over the 15-year period with 5,618 patient-years of follow-up. Per line of therapy, 915/2,029 (45.1%) patients used adalimumab, 722/2,029 (35.6%) used infliximab, 155/2,029 (7.6%) used vedolizumab, and 237/2,029 (11.7%) used ustekinumab. When used in biological agent-naive patients, there was no difference in persistence between any agent ( P > 0.05). Used after first line in biological agent-experienced CD, ustekinumab had significantly better persistence than non-ustekinumab biological agents ( P = 0.0018), vs anti-tumor necrosis factor (TNF) alpha therapy ( P = 0.006) or vedolizumab ( P < 0.001). Ustekinumab persistence was unaffected by prior biological agent exposure ( P = 0.51). After anti-TNF use, ustekinumab had superior persistence to an alternative anti-TNF agent ( P = 0.033) and to vedolizumab ( P = 0.026). Using a propensity score-matched analysis adjusted for age, immunomodulator use, and bio-exposed status, ustekinumab had superior persistence to anti-TNF ( P = 0.01). Multivariate predictors of worse persistence were the use of a non-ustekinumab biological agent (adjusted hazard ratio 2.10, P < 0.001), and bio-experienced status (adjusted hazard ratio 1.23, P < 0.001). DISCUSSION: This large national prospective database with nonhierarchical prescribing of biological agents did not identify superior persistence of any agent in bio-naive CD. However, for patients with bio-experienced CD, persistence was greater with ustekinumab.
引用
- Chetwood JD, Ko Y, Pudipeddi A, et al. Biological Agents in the Treatment of Crohn's Disease: A Propensity Score-Matched Analysis From the Prospective Persistence Australian National IBD Cohort (PANIC3) Study. Am J Gastroenterol. 2024. PMID: 38275272. doi:10.14309/ajg.0000000000002679
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。